Changes in Contrast Volume among Patients Undergoing Percutaneous Coronary Intervention: a Report from NCDR CathPCI registry
Abstract Body (Do not enter title and authors here): Background: Acute kidney injury (AKI) is the most common complication after percutaneous coronary intervention (PCI) and can be mitigated by using less iodinated contrast. The National Cardiovascular Data Registry (NCDR) supports quality improvement initiatives by providing quarterly, risk-adjusted, institutional AKI rates. However, it remains uncertain whether these efforts have reduced procedural contrast volume, particularly in high-risk patients. Aims: Examine temporal trends in contrast volume during PCI across different pre-procedural AKI risk strata. Methods: Within the NCDR CathPCI Registry, we identified PCIs performed between April 1, 2018, and December 31, 2022, and examined changes in mean contrast volume over time across different pre-procedural AKI risk strata defined by the validated NCDR AKI risk model. A multivariable hierarchical model, with the physician as a random effect, was constructed to assess the trend in contrast volume use over time. Results: Among 3,126,559 patients undergoing PCI (mean age = 66.8 ± 11.7 years, 69.4% men, and 39.9% elective procedures), contrast volume declined from a mean of 168.1±77.6 ml in Q2 2018 to 149.8±71.2 ml in Q4 2022 (p< 0.001 for trend) with the trend being consistent across AKI risk strata (Figure). After adjusting for patient and pre-procedural characteristics, the contrast volume declined by 18.9 ml (95%CI 19.1 to 18.6, P<0.001) between 2018 and 2022. Despite marked physician variability in mean contrast use, the lowest mean contrast doses were observed in patients at greatest AKI risk (>15%). Conclusions: PCI contrast administration has declined over time, and the average exposure was lowest in patients at highest risk for AKI, suggesting improved efforts to reduce AKI over time.
Ikemura, Nobuhiro
( Saint Lukes Mid America Heart Inst
, Shawnee
, Kansas
, United States
)
Chan, Paul
( Saint Luke's Mid America Heart Institute
, Kansas City
, Missouri
, United States
)
Cohen, David
( Cardiovascular Research Foundation
, New York
, New York
, United States
)
Kennedy, Kevin
( Saint Luke's Mid America Heart Institute
, Kansas City
, Missouri
, United States
)
Uzendu, Anezi
( University of Texas Southwestern
, DALLAS
, Texas
, United States
)
Kohsaka, Shun
( Keio Univeristy
, Tokyo
, Japan
)
Spertus, John
( Saint Lukes Mid America Heart Inst
, Kansas City
, Missouri
, United States
)
Author Disclosures:
Nobuhiro Ikemura:DO have relevant financial relationships
;
Research Funding (PI or named investigator):Bristol Myers Squibb:Past (completed)
| Paul Chan:DO NOT have relevant financial relationships
| David Cohen:DO have relevant financial relationships
;
Research Funding (PI or named investigator):Abbott:Active (exists now)
; Consultant:Boston Scientific:Active (exists now)
; Consultant:Medtronic:Past (completed)
; Consultant:Edwards Lifesciences:Active (exists now)
; Consultant:Abbott:Active (exists now)
; Research Funding (PI or named investigator):IRhythm:Past (completed)
; Research Funding (PI or named investigator):Zoll Medical:Active (exists now)
; Research Funding (PI or named investigator):Corvia Medical:Active (exists now)
; Research Funding (PI or named investigator):Philips:Active (exists now)
; Research Funding (PI or named investigator):CathWorks:Active (exists now)
; Research Funding (PI or named investigator):Boston Scientific:Active (exists now)
; Research Funding (PI or named investigator):Edwards Lifesciences:Active (exists now)
| kevin kennedy:No Answer
| Anezi Uzendu:DO NOT have relevant financial relationships
| Shun Kohsaka:No Answer
| John Spertus:DO have relevant financial relationships
;
Consultant:Bristol Meyers Squibb:Active (exists now)
; Consultant:Edwards Healthscients:Past (completed)
; Consultant:Abbott:Past (completed)
; Consultant:Bayer:Past (completed)
; Consultant:Terrumo:Active (exists now)
; Royalties/Patent Beneficiary:Outcomes Instruments - Copyright to SAQ, KCCQ, and PAQ:Active (exists now)
; Consultant:Alnylam:Past (completed)
; Other (please indicate in the box next to the company name):Board of Directors for Blue Cross Blue Shield of Kansas City:Active (exists now)
; Research Funding (PI or named investigator):Janssen:Active (exists now)
; Consultant:Janssen:Active (exists now)
; Consultant:Sanofi Aventis:Past (completed)
; Consultant:Imbria Pharmaceuticals:Active (exists now)
; Consultant:Cytokinetics:Active (exists now)
; Research Funding (PI or named investigator):Bristol Meyers Squibb:Active (exists now)